

Nicholas J Ashton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5436535/publications.pdf>

Version: 2024-02-01

163
papers

8,171
citations

46984

47
h-index

62565

80
g-index

176
all docs

176
docs citations

176
times ranked

6341
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433. | 4.9 | 668 |
| 2 | Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. <i>Neurology</i> , 2020, 95, e1754-e1759. | 1.5 | 304 |
| 3 | Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724. | 3.9 | 285 |
| 4 | Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599. | 15.2 | 235 |
| 5 | Steroid-Responsive Encephalitis in Coronavirus Disease 2019. <i>Annals of Neurology</i> , 2020, 88, 423-427. | 2.8 | 230 |
| 6 | A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400. | 5.8 | 219 |
| 7 | Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278. | 3.9 | 209 |
| 8 | Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471. | 4.5 | 204 |
| 9 | Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's disease continuum when only subtle changes in A β pathology are detected. <i>EMBO Molecular Medicine</i> , 2020, 12, e12921. | 3.3 | 202 |
| 10 | Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516. | 3.7 | 198 |
| 11 | Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442. | 4.1 | 186 |
| 12 | Plasma proteins predict conversion to dementia from prodromal disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 799. | 0.4 | 180 |
| 13 | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156. | 0.4 | 174 |
| 14 | Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33. | 1.0 | 163 |
| 15 | Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396. | 4.5 | 146 |
| 16 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. <i>Clinical Infectious Diseases</i> , 2021, 73, e3019-e3026. | 2.9 | 131 |
| 17 | Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5. | 2.4 | 125 |
| 18 | Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339. | 3.7 | 124 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284. | 4.9 | 121 |
| 20 | Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. <i>JAMA Neurology</i> , 2021, 78, 1108. | 4.5 | 114 |
| 21 | Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. <i>European Journal of Neurology</i> , 2021, 28, 3324-3331. | 1.7 | 109 |
| 22 | Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>EBioMedicine</i> , 2021, 70, 103512. | 2.7 | 106 |
| 23 | Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418. | 4.9 | 99 |
| 24 | Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. <i>Clinical Neurophysiology</i> , 2021, 132, 1733-1740. | 0.7 | 94 |
| 25 | Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 960-967. | 0.9 | 93 |
| 26 | Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. <i>Intensive Care Medicine</i> , 2021, 47, 39-48. | 3.9 | 90 |
| 27 | Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1141-1154. | 0.4 | 89 |
| 28 | Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. <i>Acta Neuropathologica</i> , 2022, 143, 487-503. | 3.9 | 89 |
| 29 | Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 198. | 3.0 | 87 |
| 30 | Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767. | 0.4 | 81 |
| 31 | Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976. | 4.1 | 76 |
| 32 | Fluid Biomarkers for Synaptic Dysfunction and Loss. <i>Biomarker Insights</i> , 2020, 15, 117727192095031. | 1.0 | 74 |
| 33 | Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535. | 5.3 | 73 |
| 34 | Proteomic blood profiling in mild, severe and critical COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 6357. | 1.6 | 72 |
| 35 | Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ₄₂ /A β ₄₀ and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293. | 0.4 | 72 |
| 36 | An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020, 61, 29-39. | 2.0 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Determining Amyloid- β Positivity Using 18 F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252. | 2.8 | 65 |
| 38 | Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836. | 2.7 | 65 |
| 39 | Effect of Race on Prediction of Brain Amyloidosis by Plasma A β 42/A β 40, Phosphorylated Tau, and Neurofilament Light. <i>Neurology</i> , 2022, 99, . | 1.5 | 63 |
| 40 | Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827. | 0.4 | 62 |
| 41 | Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804. | 3.7 | 60 |
| 42 | Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812. | 0.6 | 59 |
| 43 | A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220. | 4.7 | 59 |
| 44 | Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26. | 3.0 | 56 |
| 45 | Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 34-42. | 1.0 | 55 |
| 46 | Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1129-1141. | 1.2 | 55 |
| 47 | Salivary Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> , 2019, 8, 83-94. | 1.4 | 54 |
| 48 | OUP accepted manuscript. <i>Brain</i> , 2021, 144, 434-449. | 3.7 | 54 |
| 49 | Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12168. | 1.2 | 52 |
| 50 | No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 125-127. | 1.5 | 51 |
| 51 | Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1231-1241. | 0.9 | 51 |
| 52 | Blood protein predictors of brain amyloid for enrichment in clinical trials?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 48-60. | 1.2 | 50 |
| 53 | Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818. | 0.7 | 50 |
| 54 | Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. <i>Neurology</i> , 2021, 97, . | 1.5 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26. | 3.0 | 49 |
| 56 | Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid β -positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689. | 1.2 | 48 |
| 57 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488. | 0.4 | 46 |
| 58 | Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. <i>Frontiers in Neurology</i> , 2020, 11, 1054. | 1.1 | 45 |
| 59 | Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219. | 1.4 | 44 |
| 60 | Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. <i>Brain Communications</i> , 2021, 3, fcab099. | 1.5 | 43 |
| 61 | Relevance of biomarkers across different neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 56. | 3.0 | 42 |
| 62 | Plasma p τ 231, p τ 181, τ -PET Biomarkers, and Cognitive Change in Older Adults. <i>Annals of Neurology</i> , 2022, 91, 548-560. | 2.8 | 42 |
| 63 | Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 561-572. | 1.2 | 41 |
| 64 | Plasma neurofilament light chain and amyloid β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 186. | 3.1 | 41 |
| 65 | Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32. | 4.5 | 38 |
| 66 | Plasma P τ 181 to A β 242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1649-1662. | 0.4 | 37 |
| 67 | Post-acute blood biomarkers and disease progression in traumatic brain injury. <i>Brain</i> , 2022, 145, 2064-2076. | 3.7 | 37 |
| 68 | Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 17. | 3.0 | 35 |
| 69 | Amyloid processing in τ -COVID-19-associated neurological syndromes. <i>Journal of Neurochemistry</i> , 2022, 161, 146-157. | 2.1 | 35 |
| 70 | Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69. | 3.0 | 34 |
| 71 | Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837. | 2.7 | 34 |
| 72 | Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136. | 1.5 | 33 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304. | 5.8 | 33 |
| 74 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20. | 3.0 | 32 |
| 75 | Urinary metabolic phenotyping for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 21745. | 1.6 | 30 |
| 76 | Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. <i>European Journal of Neurology</i> , 2021, 28, 974-981. | 1.7 | 30 |
| 77 | Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214. | 0.9 | 30 |
| 78 | p-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098. | 3.3 | 30 |
| 79 | Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409. | 1.7 | 28 |
| 80 | Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919. | 1.2 | 27 |
| 81 | Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 41-47. | 1.1 | 26 |
| 82 | Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 65. | 3.0 | 25 |
| 83 | Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. <i>Journal of Immunology</i> , 2021, 207, 90-100. | 0.4 | 24 |
| 84 | The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085. | 3.3 | 22 |
| 85 | Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 875-887. | 0.4 | 22 |
| 86 | CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, 2614-2626. | 0.4 | 22 |
| 87 | Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. <i>Clinical Chemistry</i> , 2021, 67, 1361-1372. | 1.5 | 21 |
| 88 | Detection of Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , 2018, 91, 291-300. | 0.2 | 21 |
| 89 | Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 94. | 3.0 | 20 |
| 90 | N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848. | 3.7 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum. <i>Scientific Reports</i> , 2019, 9, 15385. | 1.6 | 19 |
| 92 | Plasma transferrin and hemopexin are associated with altered A β uptake and cognitive decline in Alzheimer's disease pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 72. | 3.0 | 19 |
| 93 | Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. <i>JAMA Neurology</i> , 2021, 78, 1525. | 4.5 | 19 |
| 94 | Plasma p-tau ₁₈₁ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 1523-1536. | 0.4 | 18 |
| 95 | Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12145. | 1.2 | 17 |
| 96 | Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 182-192. | 0.7 | 16 |
| 97 | Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073. | 1.5 | 15 |
| 98 | Brain Injury Biomarkers for Predicting Outcome After Cardiac Arrest. <i>Critical Care</i> , 2022, 26, 81. | 2.5 | 15 |
| 99 | Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. <i>Brain</i> , 2022, 145, 3546-3557. | 3.7 | 15 |
| 100 | Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225. | 1.2 | 13 |
| 101 | Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464. | 0.4 | 13 |
| 102 | The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care. <i>Journal of Neuroradiology</i> , 2022, 49, 421-427. | 0.6 | 13 |
| 103 | Gfap and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. <i>Resuscitation</i> , 2022, 170, 141-149. | 1.3 | 13 |
| 104 | Head-to-head comparison of amplified plasmonic exosome A β 42 platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021, 28, 1479-1489. | 1.7 | 11 |
| 105 | Plasma and CSF NFL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12295. | 1.2 | 11 |
| 106 | Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, . | 3.0 | 11 |
| 107 | Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 991-997. | 1.2 | 10 |
| 108 | Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 659898. | 1.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Spitting image: can saliva biomarkers reflect Alzheimer's disease?. EBioMedicine, 2021, 68, 103437. | 2.7 | 9 |
| 110 | Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188. | 3.0 | 8 |
| 111 | Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368. | 1.2 | 7 |
| 112 | Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168. | 3.0 | 7 |
| 113 | The reliability and validity of DSM 5 diagnostic criteria for neurocognitive disorder and relationship with plasma neurofilament light in a down syndrome population. Scientific Reports, 2021, 11, 13438. | 1.6 | 6 |
| 114 | Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 6 |
| 115 | A genome-wide association study of plasma phosphorylated tau181. Neurobiology of Aging, 2021, 106, 304.e1-304.e3. | 1.5 | 5 |
| 116 | Plasma sTREM2: a potential marker of cerebrovascular injury in neurodegenerative disorders. Brain, 2021, 144, 3283-3285. | 3.7 | 5 |
| 117 | Microglial activation and tau propagate jointly across Braak stages. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 4 |
| 118 | Alzheimer's disease biomarker roadmap 2020: Time for tau. Alzheimer's and Dementia, 2020, 16, e039549. | 0.4 | 3 |
| 119 | Serum Hecpudin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- β^2 Load. Journal of Alzheimer's Disease, 2020, 76, 291-301. | 1.2 | 3 |
| 120 | Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's and Dementia, 2022, , . | 0.4 | 3 |
| 121 | O β 42: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545. | 0.4 | 2 |
| 122 | Alzheimer's disease biomarker roadmap 2020: Fluid biomarkers. Alzheimer's and Dementia, 2020, 16, e039557. | 0.4 | 2 |
| 123 | Plasma p τ 181 accurately predicts Alzheimer's disease pathology at least 8 years prior to postmortem and improves the clinical characterisation of cognitive decline. Alzheimer's and Dementia, 2020, 16, e047539. | 0.4 | 2 |
| 124 | Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 2 |
| 125 | Distinctive effect of biological sex in AD-related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 2 |
| 126 | ICP β 70: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P64. | 0.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954. | 0.4 | 1 |
| 128 | Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. Alzheimer's and Dementia, 2020, 16, e039556. | 0.4 | 1 |
| 129 | Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808. | 0.4 | 1 |
| 130 | Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 355-366. | 1.2 | 1 |
| 131 | Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423. | | 1 |
| 132 | Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer's disease continuum. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 1 |
| 133 | CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 1 |
| 134 | Plasma glial fibrillary acidic protein is an early and specific marker of amyloid β pathology in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 1 |
| 135 | Plasma p τ 181 and p τ 231 offer complementary information to identify Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 1 |
| 136 | P3-108: DISCOVERY AND VALIDATION OF PLASMA BIOMARKERS RELATING TO CSF MEASURES OF ALZHEIMER'S DISEASE PATHOLOGY. , 2014, 10, P668-P668. | | 0 |
| 137 | P3-113: NOVEL CANDIDATE BLOOD PROTEOME MARKERS OF ALZHEIMER'S DISEASE BRAIN AMYLOID BURDEN: A MULTIPLEX TMT-LC/MS-MS DISCOVERY APPROACH. , 2014, 10, P669-P670. | | 0 |
| 138 | P3-154: Plasma Biomarkers of Neocortical Amyloid Burden: An in-Depth Plasma Profile Using LC-MS. Alzheimer's and Dementia, 2016, 12, P878. | 0.4 | 0 |
| 139 | O4-1002: Blood-Based Rest Protein Levels Vary by Clinical Group and are Associated with Alzheimer's Disease Biomarkers. Alzheimer's and Dementia, 2016, 12, P357. | 0.4 | 0 |
| 140 | S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321. | | 0 |
| 141 | [P3-209]: EX-VIVO VALIDATION OF PLASMA PROTEIN FIBRINOGEN GAMMA. Alzheimer's and Dementia, 2017, 13, P1016. | 0.4 | 0 |
| 142 | [P3-243]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1033. | 0.4 | 0 |
| 143 | P3-243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1165. | 0.4 | 0 |
| 144 | P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFAD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | F4â€Pâ€01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1224. | 0.4 | 0 |
| 146 | ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P65. | 0.4 | 0 |
| 147 | ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXELâ€BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P66. | 0.4 | 0 |
| 148 | Alzheimerâ€™s disease biomarker roadmap 2020: [18 F]flortaucipir. Alzheimer's and Dementia, 2020, 16, e039550. | 0.4 | 0 |
| 149 | Serum NFL as a predictor of disease progression in dementia with Lewy bodies. Alzheimer's and Dementia, 2020, 16, e041594. | 0.4 | 0 |
| 150 | Amyloidâ€ ^{âˆž} , tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2020, 16, e044444. | 0.4 | 0 |
| 151 | The effect of physical activity on CSF biomarkers of Alzheimerâ€™s disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722. | 0.4 | 0 |
| 152 | Plasma pâ€tau231 in the Alzheimerâ€™s disease continuum: A multiâ€cohort evaluation of diagnostic performance, detection of AÎ² pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 153 | Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 154 | CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: A systematic review and metaâ€analysis. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 155 | Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 156 | Mass spectrometric measurement of six siteâ€specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 157 | Plasma Pâ€tau ₁₈₁ and NfL are central nodes in a network of diagnostic, biomarker, and demographic data. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 158 | Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 159 | Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 160 | Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based population of 70â€yearâ€olds. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 161 | Association of deepâ€learningâ€derived brain computed tomography measures with cognition and bloodâ€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |
| 162 | Plasma biomarkers for the AT(N) classification and for the detection of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, . | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Population-based blood screening for pre-clinical Alzheimer's disease: a British birth cohort at age 70. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A91.2-A91. | 0.9 | 0 |